#India #Mumbai #Molecular Diagnostics #Co-Diagnostics #CoSara Diagnostics

Co-Diagnostics JV CoSara Expands Its Reach

SALT LAKE CITY, Jan. 12, 2026 — Co-Diagnostics, Inc. (Nasdaq: CODX), known informally as Co-Dx, is making notable strides in the field of molecular diagnostics with its innovative platform designed for the development of diagnostic tests. Recently, the company's Indian joint venture, CoSara Diagnostics Pvt. Ltd., has been actively working to enhance its distributor relationships across India by participating in significant regional conferences.

Attending events such as the 44th Gujarat Association of Pathologists Microbiologists (GAPM) conference and the 13th Association of Clinical Laboratory Analysts Practitioners (ACLAP) in Maharashtra, CoSara has created valuable opportunities for interaction with potential customers. These conferences allowed CoSara to present its SARAGENE® diagnostic products alongside the upcoming Co-Dx™ PCR platform, aiming to extend its foothold in the Indian diagnostics market further.

With over 40 existing distributors in India, CoSara's commitment to expanding this network signals its dedication to improving healthcare access and diagnostic capabilities. These efforts coincide with CoSara's anticipation of supporting clinical performance studies for the Co-Dx PCR Mycobacterium Tuberculosis (MTB) Test, a crucial initiative aimed at enhancing tuberculosis diagnostics in the region.

In alignment with India's Make in India initiative, CoSara is also gearing up to participate in the manufacturing of the PCR Pro™ instrument and MTB test cups. This not only reinforces CoSara's position as a local player in the diagnostic landscape but also showcases its commitment to contributing to national priorities through local production.

The PCR platform, encompassing various products including recent innovations like PCR Home™, PCR Pro™, and a mobile application is currently under review by the FDA and other regulatory entities. Although it is not yet available for commercial sale, its introduction is highly anticipated.

Through these regional conferences, CoSara is not just promoting its current products; it is engaging potential partners and creating opportunities for collaboration that could lead to significant advancements in diagnostic testing in India. Co-Diagnostics is carving out a niche for itself by capitalizing on its proprietary technology to create tests that identify genetic markers with uses beyond infectious diseases, thereby broadening the scope of its diagnostic capabilities.

As CoSara continues to fortify its relationships with distributors and stakeholders in the healthcare sector, the implications are clear: enhanced diagnostic access, more innovative testing solutions, and a partnership-driven approach to healthcare improvement. These regional engagements are a cornerstone of CoSara's strategy to maintain momentum in a rapidly evolving market, highlighting the growing importance of collaborative efforts in advancing healthcare technologies.

In summary, Co-Diagnostics and CoSara's active participation in these regional conferences illustrates their proactive approach to fostering distributor relationships and empowering the Indian healthcare landscape with advanced diagnostic solutions.